Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF

被引：0
|
作者：
Orkin, C. [1 ]
Antinori, A. [2 ]
Rockstroh, J. [3 ]
Guillen, S. Moreno [4 ]
Martorell, C. [5 ]
Molina, J. [6 ]
Lazzarin, A. [7 ]
Maggiolo, F. [8 ]
Yazdanpanah, Y. [9 ]
Andreatta, K. [10 ]
Huang, H. [11 ]
Hindman, J. [12 ]
Martin, H. [12 ]
Baeten, J. [12 ]
Pozniak, A. [13 ]
机构：
[1] Queen Mary Univ London, HIV Med, London, England
[2] Natl Inst Infect Dis, Lazzaro Spallanzani IRCCS, Rome, Italy
[3] Univ Hosp Bonn, Med Klin & Poliklin I, Bonn, Germany
[4] Hosp Ramon & Cajal, Dept Infect Dis, Madrid, Spain
[5] Res Inst, Infect Dis, Springfield, MA USA
[6] Univ Paris, Infect Dis, Paris, France
[7] San Raffaele Hosp Milan, Lazzaro Spallanzani IRCCS, Milan, Italy
[8] Azienda Osped Papa Giovanni XXIII, Infect Dis, Bergamo, Italy
[9] AP HP Hop Bichat, Infect Dis, Paris, France
[10] Gilead Sci, Clin Virol, Foster City, CA USA
[11] Gilead Sci, Biostat Virol, Foster City, CA USA
[12] Gilead Sci, Clin Dev, Foster City, CA USA
[13] Chelsea & Westminster Hosp, Clin Res, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P088
引用
收藏
页码：88 / 89
页数：2
相关论文
共 45 条
  • [1] Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF
    Pozniak, A.
    Maggiolo, F.
    Podzamczer, D.
    Yazdanpanah, Y.
    Gupta, S.
    Esser, S.
    Mounzer, K.
    Grossberg, R.
    Post, F.
    Huang, H.
    Acosta, R.
    Baeten, J.
    Hindman, J.
    Martin, H.
    Orkin, C.
    HIV MEDICINE, 2021, 22 : 125 - 125
  • [2] Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo
    Acosta, T. Parraga
    Osborn, Z.
    Lee, J. C.
    Haubrich, R. H.
    McNicholl, I.
    McKinnon, J. E.
    HIV MEDICINE, 2019, 20 : 88 - 88
  • [3] Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years
    Daar, Eric
    Orkin, Chloe
    Sax, Paul
    Koenig, Ellen
    Clarke, Amanda
    Baumgarten, Axel
    Brinson, Cynthia
    Huang, Hailin
    Martin, Hal
    HIV MEDICINE, 2022, 23 : 12 - 12
  • [4] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results
    Podzamczer, D.
    Stellbrink, H-J
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    SenGupta, D.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 18 - 18
  • [5] RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
    Degroote, Sophie
    Blomme, Evy
    Delesie, Liesbeth
    Vandekerckhove, Linos
    De Scheerder, Marie-Angelique
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 65 - 65
  • [6] B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results
    Podzamczer, D.
    Stellbrink, H.
    Orkin, C.
    Pozniak, A.
    Arribas, J.
    Koenig, E.
    Ramgopal, M.
    Baumgarten, A.
    Wei, X.
    Cheng, A.
    SenGupta, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [7] Switching to DTG/3TC Is non-inferior to continuing a TAF-based regimen at week 144: TANGO subgroup analyses
    Scholten, S.
    Ajana, F.
    Benson, P.
    Kinder, C.
    Smith, D. E.
    Olalla Sierra, J.
    Ait-Khaled, M.
    Pappa, K. A.
    Wang, R.
    Wright, J.
    Wynne, B.
    Aboud, M.
    van Wyk, J.
    Smith, K. Y.
    HIV MEDICINE, 2021, 22 : 128 - 129
  • [8] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
    Acosta, Rima K.
    Willkom, Madeleine
    Andreatta, Kristen
    Liu, Hui
    Martin, Ross
    Parvangada, Aiyappa
    Martin, Hal
    Collins, Sean
    White, Kirsten L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
  • [9] A Phase 3, randomised, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, versus ABC/DTG/3TC in treatment-naive adults at week 96
    Waters, L.
    Wohl, D.
    Yazdanpanah, Y.
    Baumgarten, A.
    Clarke, A.
    Hagins, D.
    Ramgopal, M.
    Wei, X.
    White, K.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 16 - 16
  • [10] Switching to DTG/3TC fixed-dose combination (FDC) is noninferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks: TANGO study
    van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly
    Rubach, Martin
    INFECTION, 2021, 49 (SUPPL 1) : S13 - S13
12345